Alliqua's (ALQA) MIST Therapy System Receives Expanded Medicare Reimbursement Coverage
- Oil steadies on doubts output cut will end global glut
- Western Digital (WDC) Raises Q2 Outlook
- Dollar edges up vs yen as traders eye ECB meeting for cues
- Foxconn says in preliminary discussions to expand U.S. operations
- Dave & Buster's Entertainment (PLAY) Tops Q3 EPS by 11c, Raises FY Revenue Guidance
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Alliqua BioMedical, Inc. (Nasdaq: ALQA) announced that the Company’s MIST Therapy System® is now eligible for coverage in the geographic regions covered by First Coast Service Options Inc. (“First Coast”), a Medicare Administrative Contractor, or “MAC.” The MIST Therapy System uses painless, noncontact low-frequency ultrasound to stimulate cells below the wound bed to promote the healing process. Medicare coverage for MIST Therapy now includes all Medicare Administrative Contractors.
First Coast is responsible for processing Medicare claims in Florida, Puerto Rico, and the U.S. Virgin Islands, which collectively represent approximately 58,479 providers and over 2.9 million Medicare beneficiaries. The organization is one of eight regional MACs that process Medicare claims in the United States.
With the announcement of First Coast’s decision to remove CPT code 97610 from its Noncovered Services Local Coverage Determination (“LCD” L33777), treatments performed with Alliqua’s MIST Therapy system on or after October 6, 2016, will be eligible for Medicare reimbursement when medically reasonable and necessary, and when established billing, coding and documentation guidelines are followed. As with any procedure, providers should contact their local Medicare contractor with questions concerning medical necessity.
“With the addition of Medicare coverage from First Coast, I am pleased to announce that our MIST Therapy System is now covered by all of the eight regional MACS,” said Nino Pionati, Chief Strategy and Marketing Officer of Alliqua. “I believe that our success in obtaining nationwide Medicare reimbursement coverage is largely attributable to the compelling portfolio of clinical support for our innovative MIST Therapy, which demonstrates the System’s effectiveness in accelerating the wound healing process. I would also like to thank our outstanding reimbursement team for their years of hard work and dedication in helping to expand patient and provider access to this advanced therapy, which has the potential to deliver improved patient outcomes.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Illumina (ILMN) Names New CFO
- Viking Therapeutics (VKTX) Announces FDA Orphan Drug Designation for VK0214 to Treat X-ALD
- Puma Biotech (PBYI) Commences PB272-Focused MAP
Create E-mail Alert Related CategoriesCorporate News, Management Comments
Related EntitiesRaising Prices
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!